Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Revenue of Adial Pharmaceuticals, Inc. (ADIL)
Revenue in 2023 (TTM): $
According to Adial Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Adial Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-564 | $-7,001,328 | $-7,001,890 | $-7,001,890 |
| 2022 | $ | $-60,501 | $-13,317,127 | $-12,731,918 | $-12,731,416 |
| 2021 | $ | $-55,106 | $-19,462,301 | $-19,517,403 | $-19,423,326 |
| 2020 | $ | $-564 | $-10,927,421 | $-10,892,990 | $-10,860,495 |
| 2019 | $ | $-565 | $-8,149,101 | $-8,591,429 | $-8,591,429 |
| 2018 | $ | $-563 | $-6,979,267 | $-11,631,378 | $-11,631,378 |
| 2017 | $ | $-565 | $-994,354 | $-1,139,456 | $-1,139,456 |
| 2016 | $ | $-565 | $-410,002 | $-420,200 | $-420,200 |
| 2015 | $ | $-565 | $-817,428 | $-817,993 | $-817,993 |